|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 96 No. 1 (July 1), 2000:
pp. 365-368
BRIEF REPORT
Expression of breast cancer resistance protein in blast cells
from patients with acute leukemia
Douglas D. Ross,
Judith E. Karp,
Tar T. Chen, and
L. Austin Doyle
From the University of Maryland Greenebaum Cancer Center; the
Department of Medicine, Division of Hematology/Oncology, and Department
of Epidemiology and Preventative Medicine, University of Maryland
School of Medicine; and the Baltimore Veterans Medical Center,
Baltimore, MD.
Breast cancer resistance protein (BCRP) is a novel member of the
adenosine triphosphate-binding cassette superfamily of transport proteins. Transfection and enforced expression of BCRP in
drug-sensitive cells confer resistance to mitoxantrone, doxorubicin,
daunorubicin, and topotecan. We studied blast cells from 21 acute
leukemia patients (20 acute myeloid leukemia, 1 acute lymphocytic
leukemia) for the expression of BCRP mRNA using a
quantitative reverse-transcription polymerase chain reaction assay.
BCRP mRNA expression varied more than 1000-fold among the samples
tested, with low or barely detectable expression in half of
the samples. Seven samples (33%) had relatively high
expression of BCRP mRNA. High expression of BCRP did not correlate strongly with high expression of P-glycoprotein,
suggesting that BCRP may cause resistance to certain antileukemic
drugs in P-glycoprotein-negative cases. High expression of
BCRP mRNA is sufficiently frequent in AML to warrant more extensive
investigations to determine the relation of disease subtype and
treatment outcome to BCRP expression and function.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. E. Bram, Y. Adar, N. Mesika, M. Sabisz, A. Skladanowski, and Y. G. Assaraf
Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2
Mol. Pharmacol.,
May 1, 2009;
75(5):
1149 - 1159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Poonkuzhali, J. Lamba, S. Strom, A. Sparreboom, K. Thummel, P. Watkins, and E. Schuetz
Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms
Drug Metab. Dispos.,
April 1, 2008;
36(4):
780 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev,
October 1, 2006;
86(4):
1179 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Seamon, C. A. Rugg, S. Emanuel, A. M. Calcagno, S. V. Ambudkar, S. A. Middleton, J. Butler, V. Borowski, and L. M. Greenberger
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
Mol. Cancer Ther.,
October 1, 2006;
5(10):
2459 - 2467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Becton, G. V. Dahl, Y. Ravindranath, M. N. Chang, F. G. Behm, S. C. Raimondi, D. R. Head, K. C. Stine, N. J. Lacayo, B. I. Sikic, et al.
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421
Blood,
February 15, 2006;
107(4):
1315 - 1324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Henriksen, J. U. Fog, T. Litman, and U. Gether
Identification of Intra- and Intermolecular Disulfide Bridges in the Multidrug Resistance Transporter ABCG2
J. Biol. Chem.,
November 4, 2005;
280(44):
36926 - 36934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Clin. Cancer Res.,
November 1, 2005;
11(21):
7764 - 7772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Henriksen, U. Gether, and T. Litman
Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2
J. Cell Sci.,
April 1, 2005;
118(7):
1417 - 1426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, et al.
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
Cancer Res.,
March 1, 2005;
65(5):
1770 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ozvegy-Laczka, G. Varady, G. Koblos, O. Ujhelly, J. Cervenak, J. D. Schuetz, B. P. Sorrentino, G.-J. Koomen, A. Varadi, K. Nemet, et al.
Function-dependent Conformational Changes of the ABCG2 Multidrug Transporter Modify Its Interaction with a Monoclonal Antibody on the Cell Surface
J. Biol. Chem.,
February 11, 2005;
280(6):
4219 - 4227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Benderra, A.-M. Faussat, L. Sayada, J.-Y. Perrot, D. Chaoui, J.-P. Marie, and O. Legrand
Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias
Clin. Cancer Res.,
December 1, 2004;
10(23):
7896 - 7902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ozvegy-Laczka, T. Heged""s, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Mol. Pharmacol.,
June 1, 2004;
65(6):
1485 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zhang, X. Yang, and M. E. Morris
Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport
Mol. Pharmacol.,
May 1, 2004;
65(5):
1208 - 1216.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Boyer, E. G. McLean, S. Aroori, P. Wilson, A. McCulla, P. D. Carey, D. B. Longley, and P. G. Johnston
Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan
Clin. Cancer Res.,
March 15, 2004;
10(6):
2158 - 2167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, K. Goto, Y. Nishiwaki, T. Kodama, M. Suga, and A. Ochiai
Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
March 1, 2004;
10(5):
1691 - 1697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, C G Schalkwijk, G L Scheffer, R J Scheper, and G Jansen
Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF{alpha}
Ann Rheum Dis,
February 1, 2004;
63(2):
138 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Brooks, H. Minderman, K. L. O'Loughlin, P. Pera, I. Ojima, M. R. Baer, and R. J. Bernacki
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
Mol. Cancer Ther.,
November 1, 2003;
2(11):
1195 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Leonard, T. Fojo, and S. E. Bates
The Role of ABC Transporters in Clinical Practice
Oncologist,
October 1, 2003;
8(5):
411 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, J. Tsurutani, Y. Nakamura, S. Doi, T. Kitazaki, K. Sugahara, et al.
Expression and Functional Analyses of Breast Cancer Resistance Protein in Lung Cancer
Clin. Cancer Res.,
August 1, 2003;
9(8):
3052 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross
Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients
Clin. Cancer Res.,
August 1, 2003;
9(9):
3320 - 3328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim
Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy
Mol. Cancer Ther.,
July 1, 2003;
2(7):
685 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rajendra, M. K. Gounder, A. Saleem, J. H. M. Schellens, D. D. Ross, S. E. Bates, P. Sinko, and E. H. Rubin
Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin
Cancer Res.,
June 15, 2003;
63(12):
3228 - 3233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Janvilisri, H. Venter, S. Shahi, G. Reuter, L. Balakrishnan, and H. W. van Veen
Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis
J. Biol. Chem.,
May 30, 2003;
278(23):
20645 - 20651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Burger, J. A. Foekens, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, E. A. C. Wiemer, G. Stoter, and K. Nooter
RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response
Clin. Cancer Res.,
February 1, 2003;
9(2):
827 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Abbott, A.-M. Colapietro, Y. Barnes, F. Marini, M. Andreeff, and B. P. Sorrentino
Low levels of ABCG2 expression in adult AML blast samples
Blood,
December 15, 2002;
100(13):
4594 - 4601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ozvegy, A. Varadi, and B. Sarkadi
Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. MODULATION OF SUBSTRATE SPECIFICITY BY A POINT MUTATION
J. Biol. Chem.,
December 6, 2002;
277(50):
47980 - 47990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. van der Kolk, E. Vellenga, G. L. Scheffer, M. Muller, S. E. Bates, R. J. Scheper, and E. G. E. de Vries
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia
Blood,
May 15, 2002;
99(10):
3763 - 3770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Allen and A. H. Schinkel
Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2)
Mol. Cancer Ther.,
April 1, 2002;
1(6):
427 - 434.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Faneyte, P. M. P. Kristel, M. Maliepaard, G. L. Scheffer, R. J. Scheper, J. H. M. Schellens, and M. J. van de Vijver
Expression of the Breast Cancer Resistance Protein in Breast Cancer
Clin. Cancer Res.,
April 1, 2002;
8(4):
1068 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
